Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a)
Primary result · Major adverse cardiovascular event (death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or urgent coronary revascularization)Result — go to the resultHazard ratio 1.02 95% CI 0.90–1.15Authors' conclusion
Pelacarsen did not result in a lower risk of major adverse cardiovascular events than placebo at a median follow-up of 4.7 years. (Funded by Novartis; Lp[a]HORIZON ClinicalTrials.gov number, NCT04023552.)See also in NEJM Evidence: Extended Analyses of Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a).
Study context
- Population
- Patients with preexisting cardiovascular disease and a lipoprotein(a) level of at least 70 mg per deciliterunderwent randomization, 8322 included in the efficacy analysis
- Participants
- 8,350 patients
- Comparison
- Pelacarsen vs placebo
- Pelacarsenn = 4,157
- Placebon = 4,165reference
- Primary endpoint
- Major adverse cardiovascular event:
- Death from cardiovascular causes
- Nonfatal myocardial infarction
- Nonfatal stroke
- Urgent coronary revascularization
- Follow-up
- Median 4.7 years
Primary result
Major adverse cardiovascular event…
Pelacarsenvs Placebo
hazard ratio 1.02 (95% CI 0.90–1.15); P = 0.76
As reported in the abstract
Further findings
Lipoprotein(a) level · 12 months
| Outcome | Pelacarsen | Placebo | Hazard ratio (95% CI) | P value | |
|---|---|---|---|---|---|
| Primary end point among patients with baseline lipoprotein(a) of at least 90 mg per deciliter (subgroup) | 12.3% | 12.3% | 1.00 (0.87–1.15) | P = 0.99 | |
| 0.512Hazard ratio (log scale) |
- Lipoprotein(a) level: median baseline 236 nmol per liter
Safety
Serious adverse events
Original publication
Pelacarsen and Cardiovascular Outcomes in Patients with High Lipoprotein(a). N Engl J Med. Published 7 November 2026. doi:10. 1056/ nejmoa2610159
Composed by AI from the published abstract and checked against it. How Briefs are made →